TrialJournal of diabetes investigation2019

Which is better, high-dose metformin monotherapy or low-dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low-dose metformin monotherapy? A randomized, cross-over, continuous glucose monitoring-based pilot study.

Hiroshi Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.